ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0085

Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease

Kensuke Suga1, Amara Seng2, Changfu Yao3, Tanyalak Parimon3, Youn Jung Choi2, Justyna Fert-Bober4, Barry Stripp3, Jon Giles5, Peter Chen3 and Nunzio Bottini6, 1Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, 2Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 3Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 4Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 5Cedars Sinai Medical Center, Los Angeles, CA, 6Cedars Sinai Medical Center, Beverly Hills, CA

Meeting: ACR Convergence 2025

Keywords: interstitial lung disease, rheumatoid arthritis, T Cell, Tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in approximately 10% of RA patients and is associated with poor prognosis. Recent single-cell RNA-sequencing (scRNA-seq) analysis have revealed the effects of the cellular makeup and molecular pathways on pathological changes in several lung diseases, but little is known about RA-ILD. This study aimed to characterize immune/epithelial cells in RA-ILD through scRNA-seq analysis.

Methods: We processed explant tissues from 5 RA-ILD patients, 3 non-RA connective tissue disease (CTD)-ILD (2 with dermatomyositis (DM) and 1 mixed connective tissue disease (MCTD)), and 4 control patients. CD45+CD31-EpCAM- immune cells and CD45-CD31-EpCAM+ epithelial cells were FACS sorted and subjected to scRNA-seq. Ingenuity pathway analysis was used to perform upstream regulator analysis.

Results: We analyzed 184,814 cells after quality-control filtering and identified 18 distinct cell clusters (Figure 1). By differential abundance analysis, we found that AT2 cells were 65% lower in abundance in RA-ILD lung tissue compared with control lung tissue, and 10% lower in RA-ILD compared with non-RA CTD-ILD. We identified a reciprocal higher abundance of other epithelial cell types (basal cells, club cells, and ciliated cells). We also found fewer FCN1+ CD14+ macrophages and more SPP1+ macrophages in RA-ILD lungs. We calculated the number of differentially expressed genes (DEGs) in each cell cluster between the disease groups (RA vs control and RA vs CTD) and found that AT2 cells, club cells, FCN1+ CD14+ macrophages, FABP4+ macrophages, and SPP1+ macrophage had a higher number of DEGs (Figure 2). Upstream regulator analysis revealed that TNFa was potentially activated as an upstream molecule which drived differential changes in RA-ILD AT2 cells. T cell sub-clustering analysis revealed that peripheral T cells (Tph) are exclusively found in RA-ILD lungs (Figure 3).

Conclusion: There was heterogeneity in several key cell types, such as AT2 cells, club cells, FCN1+ CD14+ macrophages, FABP4+ macrophages, SPP1+ macrophages, and Tph cells between RA-ILD, non-RA CTD-ILD, and control lungs. An upstream regulator analysis suggested that TNF signaling might be involved in the phenotypic change of AT2 cells in RA-ILD. Our study suggests that immune/epithelial cell abnormalities underlie the pathogenesis of RA-ILD.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Suga: None; A. Seng: None; C. Yao: None; T. Parimon: None; Y. Choi: None; J. Fert-Bober: None; B. Stripp: None; J. Giles: AbbVie/Abbott, 2, Eli Lilly, 2, Genentech, 2, Merck/MSD, 2, Novartis, 2, Pfizer, 2, Sana, 2; P. Chen: Gilead, 1; N. Bottini: Merck/MSD, 2.

To cite this abstract in AMA style:

Suga K, Seng A, Yao C, Parimon T, Choi Y, Fert-Bober J, Stripp B, Giles J, Chen P, Bottini N. Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/single-cell-rna-seq-revealed-immune-epithelial-cell-abnormalities-underlying-the-pathogenesis-of-rheumatoid-arthritis-related-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-cell-rna-seq-revealed-immune-epithelial-cell-abnormalities-underlying-the-pathogenesis-of-rheumatoid-arthritis-related-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology